MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2023 International Congress

    PFBC and dystonia: description of a cohort and peculiar cases

    G. Bonato, S. Andretta, C. Bertolin, L. Salviati, M. Carecchio (Padova, Italy)

    Objective: To describe dystonia in a PFBC cohort Background: Primary familial brain calcification (PFBC) is a rare neurodegenerative disorder characterized by calcium deposition in basal…
  • 2023 International Congress

    An Algorithmic Approach to Assessing Cognitive Functioning in Individuals with REM Sleep Behavior Disorder

    G. Schneider, A. Avidan, D. Bliwise, S. Criswell, E. During, J. Elliott, L. Forsberg, J-F. Gagnon, M. Howell, D. Huddleston, A. Keil, J. Lee-Iannotti, M. Lim, J. Mcleland, M. Miglis, E. Mignot, R. Postuma, C. Schenck, D. Shprecher, E. ST. Louis, A. Videnovic, B. Boeve, Y-E. Ju, J. Fields (Rochester, USA)

    Objective: To apply an algorithmic approach to interpretation of cognitive data to assess cognitive impairment in RBD participants. Background: Cognitive changes in emerging neurodegenerative disease…
  • 2023 International Congress

    DaT-Scans Have Limited Utility in Predicting Treatment Response to Ventriculoperitoneal Shunts in Normal Pressure Hydrocephalus

    J. Ma, M. Hamed, D. Victor, T. Kay, M. Salgado (Brooklyn, USA)

    Objective: To determine usefulness of DaT-SPECT imaging in the management of normal pressure hydrocephalus (NPH). Background: Dopamine transporter single-photon emission computed tomography (DaT-SPECT) imaging is…
  • 2023 International Congress

    Subjective cognitive complaints in participants of the Healthy Brain Ageing (HeBA) study

    S. Jónsdóttir, C. Pauly, O. Tsurkalenko, E. Thiry, AM. Hanff, T. Marques, C. Horlings, A. Garrido, C. Vega, S. Schade, P. Mahlknecht, C. Gomes, S. Ghosh, K. Rege, R. Rawal, D. Mcintyre, K. Seppi, M. Martí, C. Trenkwalder, E. Tolosa, W. Poewe, V. Satagopam, R. Krüger, B. Mollenhauer (Heisdorf, Luxembourg)

    Objective: To investigate the prevalence of subjective cognitive complaints (SCC) from Healthy Brain Ageing Study (HeBA) participants in Luxembourg, and explore risk factors prevalence which…
  • 2023 International Congress

    Olfactory neurons’ Substance P is highly expressed in Parkinson’s disease reflecting gastrointestinal dysfunction

    T. Schirinzi, D. Maftei, P. Grillo, R. Bovenzi, J. Bissacco, C. Simonetta, H. Zenuni, FM. Passali, S. Di Girolamo, A. Stefani, NB. Mercuri, R. Lattanzi, C. Severini (Rome, Italy)

    Objective: To elucidate the role of Substance P in PD through molecular characterization of patients’ olfactory neurons. Background: Substance P is a neuropeptide largely expressed…
  • 2023 International Congress

    Incidence of childhood trauma in patients with functional movement disorder and its impact on motor symptoms severity

    L. Nováková, T. Serranová, P. Sojka, D. Voženílek (Praha, Czech Republic)

    Objective: To assess the impact of self-reported childhood traumatic experience on motor symptoms severity in a group of patients with functional movement disorder (FMD). Background:…
  • 2023 International Congress

    Effect of variants in COMT and UGT1A genes on clinical response in patients with Parkinson’s disease treated with opicapone

    E. Ojeda-Lepe, S. García-Díaz, R. Díaz Belloso, L. Muñoz-Delgado, S. Jesús, MT. Periñán, B. Benítez Zamora, AD. Adarmes-Gómez, D. Macías-García, M. Martín-Bornez, M. Bonilla-Toribio, D. Buiza-Rueda, R. Pineda-Sánchez, F. Carrillo, P. Gómez-Garre, P. Mir (Seville, Spain)

    Objective: To identify genetic variants associated with different clinical responses in patients with Parkinson’s disease(PD) treated with opicapone. Background: Opicapone is a catechol‐O‐methyltransferase(COMT) inhibitor used…
  • 2023 International Congress

    PASADENA 1-year open-label extension

    G. Pagano, A. Reyes, A. Monnet, M. Martinec, N. Shariati, T. Simuni, K. Marek, R. Postuma, N. Pavese, F. Stocchi, K. Taylor, H. Svoboda, P. Fontoura, G. Kerchner, R. Doody, A. Bonni, T. Nikolcheva (Basel, Switzerland)

    Objective: To describe the results of PASADENA 1-year open-label extension (OLE). Background: Prasinezumab is a humanized monoclonal antibody that binds aggregated alpha-synuclein with the potential…
  • 2023 International Congress

    Continuous algorithmic insights into PD motor symptoms and individual treatment response

    M. Sander, FMJ. Pfister, G. Höglinger, J. Levin, A. Ceballos-Baumann, UM. Fietzek (Munich, Germany)

    Objective: To quantify the short-duration levodopa response using high resolution data derived from a wrist sensor and processed with advanced deep learning methods Background: The…
  • 2023 International Congress

    Open-label Extension Study of Long-term Safety and Tolerability of Foslevodopa/Foscarbidopa for Treatment of Advanced Parkinson’s Disease

    V. Fung, J. Aldred, F. Bergquist, E. Danielsen, A. Jeong, J. Jia, A. Spiegel, S. Talapala, C. Carroll (Westmead, Australia)

    Objective: To evaluate long-term safety/tolerability of foslevodopa/foscarbidopa (LDP/CDP) in patients with advanced Parkinson’s disease (aPD) in a phase 3 open-label extension (OLE) study. Background: LDP/CDP…
  • « Previous Page
  • 1
  • …
  • 303
  • 304
  • 305
  • 306
  • 307
  • …
  • 1554
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • To be or not to bupropion: a drug-induced parkinsonism?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • An atypical and interesting feature of Parkinson´s disease
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley